Anle138b is an aggregation inhibitor that modulates the formation of pathological oligomers of both prion and -synuclein.1 In mouse models of prion and diseases and Parkinsons disease, Anle138b strongly inhibited oligomer formation, neuronal degeneration, and disease progression even after disease onset.1,2 Anle138b has delayed disease progression and prevented motor decline in multiple neurodegenerative models.3-6 Treatment of melanoma cells with anle138b caused massive cell death via major dysregulation of autophagy revealing a protective effect of -synuclein on autophagy in these cells.7 Orally bioavailable and able to cross the blood-brain barrier.
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten
